Development and characterization of magnetic iron oxide nanoparticles with a cisplatin-bearing polymer coating for targeted drug delivery

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 3659-3676

  Unterweger, Harald ^a   Tietze, Rainer ^a   Janko, Christina ^a   Zaloga, Jan ^a   Lyer, Stefan ^a   Dürr, Stephan ^a   Taccardi, Nicola ^b   Goudouri, Ourania Menti ^b   Hoppe, Alexander ^b   Eberbeck, Dietmar ^c   Schubert, Dirk W ^b   Boccaccini, Aldo R ^b   Alexiou, Christoph ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c PHYSIKALISCH TECHNISCHE BUNDESANSTALT   (Germany)

Author keywords

Dextran; Hyaluronic acid; Magnetic drug targeting; Superparamagnetic iron oxide nanoparticles

Indexed keywords

CISPLATIN; DEXTRAN; DRUG CARRIER; HYALURONIC ACID; MAGNETITE NANOPARTICLE;

CELL DEATH; CELL PROLIFERATION; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HUMAN; JURKAT CELL LINE; PARTICLE SIZE; TUMOR CELL LINE;

CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DEXTRANS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; HYALURONIC ACID; JURKAT CELLS; MAGNETITE NANOPARTICLES; PARTICLE SIZE;

EID: 84905842856     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S63433     Document Type: Article

References (54)

1. Tietze R, Lyer S, Durr S, Alexiou C. Nanoparticles for cancer therapy using magnetic forces. Nanomedicine (Lond). 2012;7(3):447-457.
2. Alexiou C, Tietze R, Schreiber E, et al. Cancer therapy with drug loaded magnetic nanoparticles - magnetic drug targeting. J Magn Magn Mater. 2011;323(10):1404-1407.
3. Tietze R, Jurgons R, Lyer S, et al. Quantification of drug-loaded magnetic nanoparticles in rabbit liver and tumor after in vivo administration. J Magn Magn Mater. 2009;321(10):1465-1468.
4. Alexiou C, Diehl D, Henninger P, et al. A high field gradient magnet for magnetic drug targeting. IEEE Appl Supercond. 2006;16(2): 1527-1530.
5. Seliger C, Jurgons R, Wiekhorst F, et al. In vitro investigation of the behaviour of magnetic particles by a circulating artery model. J Magn Magn Mater. 2007;311(1):358-362.
6. Cheng L, Jin C, Lv W, Ding Q, Han X. Developing a highly stable PLGA-mPEG nanoparticle loaded with cisplatin for chemotherapy of ovarian cancer. PLoS One. 2011;6(9):e25433-e25433.
7. Tietze R, Lyer S, Durr S, et al. Efficient drug-delivery using magnetic nanoparticles-biodistribution and therapeutic effects in tumour bearing rabbits. Nanomedicine. 2013;9(7):961-971.
8. Janko C, Dürr S, Munoz L, et al. Magnetic drug targeting reduces the chemotherapeutic burden on circulating leukocytes. Int J Mol Sci. 2013; 14(4):7341-7355.
9. Bealle G, Di CR, Kolosnjaj-Tabi J, et al. Ultra magnetic liposomes for mr imaging, targeting, and hyperthermia. Langmuir. 2012;28(32): 11834-11842.
10. Alexiou C, Tietze R, Schreiber E, Lyer S. [Pharmakotherapie mittels Nanomedizin]. Der Onkologe. 2011;17(5):405-412. German.
11. Dorniani D, Hussein MZ, Kura AU, Fakurazi S, Shaari AH, Ahmad Z. Preparation of Fe3O4 magnetic nanoparticles coated with gallic acid for drug delivery. Int J Nanomedicine. 2012;7:5745-5756.
12. Wahajuddin, Arora S. Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers. Int J Nanomedicine. 2012;7: 3445-3471.
13. Zhao Y, Dunnill CW, Zhu Y, et al. Low-temperature magnetic properties of hematite nanorods. Chem Mater. 2007;19(4):916-921.
14. Shi S, Jia JF, Guo XK, et al. Toxicity of iron oxide nanoparticles against osteoblasts. J Nanopart Res. 2012;14(9):1091.
15. Lyer S, Tietze R, Jurgons R, et al. Visualisation of tumour regression after local chemotherapy with magnetic nanoparticles - a pilot study. Anticancer Res. 2010;30(5):1553-1557.
16. Alexiou C, editor. Nanomedicine: Basic and Clinical Applications in Diagnostics and Therapy. Volume 2. Basel, Switzerland: Karger; 2011.
17. Lyer S, Tietze R, Dürr S, et al. Diagnostic imaging in cancer therapy with magnetic nanoparticles. In: Buzug TM, Borgert J, editors. Magnetic Particle Imaging. Volume 140. Heidelberg, Germany: Springer Verlag; 2012.
18. Brunke O, Odenbach S, Jurgons R, Alexiou C, Hilger I, Beckmann F. Determination of the magnetic particle distribution in tumour tissue by means of x-ray tomography. J Phys Condens Matter. 2006; 18(38):S2903.
19. Tietze R, Rahn H, Lyer S, et al. Visualization of superparamagnetic nanoparticles in vascular tissue using XmuCT and histology. Histochem Cell Biol. 2011;135(2):153-158.
20. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348(25):2491-2499.
21. Kau RJ, Alexiou C, Stimmer H, Arnold W. Diagnostic procedures for detection of lymph node metastases in cancer of the larynx. ORL J Otorhinolaryngol Relat Spec. 2000;62(4):199-203.
22. Kim DK, Zhang Y, Voit W, Rao KV, Muhammed M. Synthesis and characterization of surfactant-coated superparamagnetic monodispersed iron oxide nanoparticles. J Magn Magn Mater. 2001;225(1-2):30-36.
23. Carmen Bautista M, Bomati-Miguel O, del Puerto Morales M, Serna CJ, Veintemillas-Verdaguer S. Surface characterisation of dextran-coated iron oxide nanoparticles prepared by laser pyrolysis and coprecipitation. J Magn Magn Mater. 2005;293(1):20-27.
24. Pardoe H, Chua-anusorn W, St Pierre TG, Dobson J. Structural and magnetic properties of nanoscale iron oxide particles synthesized in the presence of dextran or polyvinyl alcohol. J Magn Magn Mater. 2001;225(1-2):41-46.
25. Kamat M, El-Boubbou K, Zhu DC, et al. Hyaluronic acid immobilized magnetic nanoparticles for active targeting and imaging of macrophages. Bioconjug Chem. 2010;21(11):2128-2135.
26. Lee YT, Woo K, Choi KS. Preparation of water-dispersible and biocompatible iron oxide nanoparticles for MRI agent. IEEE Trans Nanotechnol. 2008;7(2):111-114.
27. Lapcik L Jr, Lapcik L, De Smedt S, Demeester J, Chabrecek P. Hyaluronan: preparation, structure, properties, and applications. Chem Rev. 1998;98(8):2663-2684.
28. Laurent TC, Fraser JR. Hyaluronan. FASEB J. 1992;6(7):2397-2404.
29. Laurent TC, Laurent UB, Fraser JR. Functions of hyaluronan. Ann Rheum Dis. 1995;54(5):429-432.
30. Raman R, Sasisekharan V, Sasisekharan R. Structural insights into biological roles of protein-glycosaminoglycan interactions. Chem Biol. 2005;12(3):267-277.
31. Noro R, Yoshimura A, Yamamoto K, et al. Alternating chemotherapy with amrubicin plus cisplatin and weekly administration of irinotecan plus cisplatin for extensive-stage small cell lung cancer. Anticancer Res. 2013;33(3):1117-1123.
32. Sunwoo JB. A cisplatin-resistant subpopulation of mesenchymal-like cells in head and neck squamous cell carcinoma. Cell Cycle. 2011; 10(17):2834-2835.
33. Ratanapharn A. New insights into cellular responses to cisplatin. In: Kojima T, Morita Y, editors. Cisplatin: Pharmacology, Clinical Uses and Adverse Effects. Hauppauge, NY, USA: Nova Science Publishers Inc.; 2012.
34. Wang G, Reed E, Li QQ. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer. Oncol Rep. 2004;12(5): 955-965.
35. Carrick S, Ghersi D, Wilcken N, Simes J. Platinum containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2004;2:CD003374.
36. Jeong YI, Kim ST, Jin SG, et al. Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation. J Pharm Sci. 2008;97(3):1268-1276.
37. Gura E, Hückel M, Müller PJ. Specific degradation of hyaluronic acid and its rheological properties. Polym Degrad Stabil. 1998;59(1-3): 297-302.
38. Lee HG, Cowman MK. An agarose gel electrophoretic method for analysis of hyaluronan molecular weight distribution. Anal Biochem. 1994;219(2):278-287.
39. Cullity BD, Stock SR. Elements of X-Ray Diffraction. Upper Saddle River, NJ, USA: Prentice Hall; 2001.
40. Dokuzovic L. Kolorimetrie-Photometrie. Available from: http://www.lickl.net/doku/photo.pdf. Accessed June 8, 2014.
41. Eberbeck D, Wiekhorst F, Wagner S, Trahms L. How the size distribution of magnetic nanoparticles determines their magnetic particle imaging performance. Appl Phys Lett. 2011;98:1-3.
42. Nishiyama N, Okazaki S, Cabral H, et al. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res. 2003;63(24):8977-8983.
43. Dürr S, Lyer S, Mann J, et al. Real-time cell analysis (RTCA) of human cancer cell lines after chemotherapy with functionalized magnetic nanoparticles. Anticancer Res. 2011;31(5):1966-1967.
44. Salazar-Alvarez G, Muhammed M, Zagorodni AA. Novel flow injection synthesis of iron oxide nanoparticles with narrow size distribution. Chem Eng Sci. 2006;61(14):4625-4633.
45. Mohapatra S, Pramanik N, Ghosh SK, Pramanik P. Synthesis and characterization of ultrafine poly(vinylalcohol phosphate) coated magnetite nanoparticles. J Nanosci Nanotechnol. 2006;6(3):823-829.
46. Cornell RM, Schwertmann U. Crystal structure. In: The Iron Oxides: Structure, Properties, Reactions, Occurences and Uses. John Wiley & Sons: New York, NY, USA; 2004.
47. Bogdanov AA Jr, Martin C, Weissleder R, Brady TJ. Trapping of dextran-coated colloids in liposomes by transient binding to aminophospholipid: preparation of ferrosomes. Biochim Biophys Acta. 1994; 1193(1):212-218.
48. Morales MP, Veintemillas-Verdaguer S, Montero MI, et al. Surface and internal spin canting in γ-Fe2O3 nanoparticles. Chem Mater. 1999;11(11):3058-3064.
49. Murai T, Kawashima H. A simple assay for hyaluronidase activity using fluorescence polarization. Biochem Biophys Res Commun. 2008;376(3): 620-624.
50. Sugahara KN, Hirata T, Hayasaka H, Stern R, Murai T, Miyasaka M. Tumor cells enhance their own CD44 cleavage and motility by generating hyaluronan fragments. J Biol Chem. 2006;281(9):5861-5868.
51. Munoz LE, Maueroder C, Chaurio R, Berens C, Herrmann M, Janko C. Colourful death: six-parameter classification of cell death by flow cytometry - dead cells tell tales. Autoimmunity. 2013;46(5): 336-341.
52. Raber J, Zhu C, Eriksson LA. Theoretical study of cisplatin binding to DNA: the importance of initial complex stabilization. J Phys Chem B. 2005;109(21):11006-11015.
53. Zwelling LA, Filipski J, Kohn KW. Effect of thiourea on survival and DNA cross-link formation in cells treated with platinum(II) complexes, L-phenylalanine mustard, and bis(2-chloroethyl)methylamine. Cancer Res. 1979;39(12):4989-4995.
54. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc. 2006;1(3):1458-1461.